3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
16
Urogenital Neoplasms
2
Urinary Bladder Neoplasms
2
Urothelial Cancer
1
Urologic Neoplasms
1
Urologic Diseases
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Radiation Injuries
1
Prostate Adenocarcinoma
1
Neoplasms by Site
1
Neoplasms
1
Melanoma
1
Male Urogenital Diseases
1
Lymphatic Metastasis
1
Infiltrating Bladder Urothelial Carcinoma
1
Genital Neoplasms, Male
1
Female Urogenital Diseases
1
Encopresis
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Mitomycin
3
vofatamab
2
pembrolizumab
2
Nivolumab
2
Gemcitabine
2
Cystectomy
2
Cisplatin
2
B701 protein, Human herpesvirus 6
2
valrubicin
1
tislelizumab
1
relatlimab
1
enzalutamide
1
enfortumab vedotin
1
durvalumab
1
Water
1
Urinary Diversion
1
Standard of Care
1
Radiosurgery
1
Radiation Dose Hypofractionation
1
Multiparametric Magnetic Resonance Imaging
1
Microscopy
1
Immunonutrition Diet
1
Immune Checkpoint Inhibitors
1
Gels
1
Fluorouracil
1
Docetaxel
1
Cystoscopy
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urinary Bladder Diseases
×
Radiation Dose Hypofractionation
×
Genitourinary
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled